Decreased Basal Levels of Glucagon-Like Peptide-1 after Weight Loss in Obese Subjectsde Luis D.A. · Gonzalez Sagrado M. · Conde R. · Aller R. · Izaola O.
Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega, University of Valladolid, Valladolid, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: Basal glucagon-like peptide-1 (GLP-1) concentrations seem to be attenuated in obese subjects, although statistical significance is unclear. Only a few studies have investigated the effect of weight reduction on GLP-1 concentrations and have found unclear results. The aim of the present study was to determine whether subjects who lose weight on a hypocaloric diet experience the same change in circulating GLP-1 levels as subjects who do not lose weight. Material and Methods: A population of 99 obese nondiabetic outpatients was analyzed in a prospective way. Weight and blood pressure were determined. Basal glucose, C-reactive protein, insulin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and basal GLP-1 blood levels were measured before and after 3 months of hypocaloric diet. Bipolar impedance examination was performed in all patients to assess body composition. The lifestyle modification program consisted of a hypocaloric diet (1,520 kcal, 52% carbohydrates, 25% lipids and 23% proteins). The exercise program consisted of aerobic exercise for at least 3 times per week (60 min each). Results: Ninety-nine patients (20 male/79 female) gave informed consent and were enrolled in the study. Fourteen patients (2 male/12 female) did not lose weight (group I: weight increase of 2 ± 1.1 kg, NS) and 75 patients (18 male/67 female) lost weight (group II, weight loss of 4 ± 1.6 kg, p < 0.05). Weight, body mass index, fat mass, waist circumference, insulin, HOMA, LDL cholesterol, triglycerides and systolic blood pressure improved in group II, without significant statistical changes in group I. In group I, basal GLP-1 levels remained unchanged (7.4 ± 3.1 vs. 7.15 ± 3.6 ng/ml, NS). In group II, GLP-1 levels decreased significantly (8.4%, 6.88 ± 2.5 vs. 6.3 ± 2.4 ng/ml, p < 0.05). In the multivariate analysis with a dependent variable (levels of GLP-1 after hypocaloric diet adjusted by age and sex), only insulin levels remained as an independent predictor in the model (F = 5.9; p < 0.05), with an increase of 0.6 ng/ml (CI 95%: 0.1–1.1) in GLP-1 concentrations with each 1-mIU/ml increase of insulin. Conclusion: Hypocaloric diet decreased GLP-1 levels in patients with weight loss with a significant improvement in anthropometric parameters and cardiovascular risk factors. Nevertheless, patients without weight loss after dietary treatment exhibited unchanged GLP-1 levels. Basal insulin correlates with basal GLP-1.
© 2007 S. Karger AG, Basel
- Meier U, Gressner AM: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem 2004;50:1511–1525.
- Westerterp-Plantenga MS: Analysis of energy density of food in relation to energy intake regulation in human subjects. Br J Nutr 2001;85:351–361.
- Blundell JE, Lawton CL, Hill AJ: Mechanisms of appetite control and their abnormalities in obese patients. Horm Res 1993;39:72–76.
- Blundell JE, Näslund E: Glucagon-like peptide-1, satiety and appetite control. Br J Nutr 1999;81:259–160.
- Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107:1848–1855
- Näslund E, Barkeling B, King N, et al: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23:304–311.
- Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R: Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 1996:38:916–919.
- Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A: The role of postprandial releases of insulin and incretin hormones in meal-induced satiety: effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25:1206–1214.
Cigaina V, Hirschberg Al: Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin. Obes Res 2003;111:1456–1462.
- Damci T, Yalin S, Balci H: Orlistat augments postprandial increases in GLP-1 in obese type 2 diabetic patients. Diabetes Care 2004;27:1077–1080.
- Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–414.
Pichard C, Slosman D, Hirschel B, Kyle U: Bioimpedance analysis in AIDS patients: an improved method for nutritional follow-up. Clin Res 1993;41:53.
- Adam TCM, Jocken J, Westerterp-Plantenga MS: Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005;13:710–715.
- Näslund E, Gryback P, Hellström PM: Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387–392.
- Westerterp-Plantenga MS, Lejeune MP, Nijs I, van Ooijen M, Kovacs EM: High protein intake sustains weight maintenance after body weight loss in humans. Int J Obes Relat Metab Disord 2004;28:57–61.
- Ranganath L, Norris F, Morgan L, Wright J, Marks V: The effect of circulating non-esterified fatty acids on the enteroinsular axis. Eur J Clin Invest 1999;29:27–32.
- Rissanen P, Fransila-Kallunki A, Rissanen A: Cardiac parasympathetic activity is increased by weight loss in healthy obese women. Obes Res 2001;9:637–643.
- Goldstone AP, Morgan I, Mercer JG: Effect of leptin on hypothalamic GLP-1 peptide and brain stem pre-proglucagon mRNA. Biochem Biophys Res Commun 2000;269:331–335.
- Valverde I, Puente J, Martin-Duce A, Molina L, Lozano O, Sancho V, Malaisse WJ, Villanueva-Penacarrillo ML: Changes in glucagon-like peptide (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005;15:387–397.
- Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002;440:269–279.
- Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, et al: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005;115:3554–3563.
- Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993;138:159–166.
- Choi YH, Anderson GH: An interaction between hypothalamic glucagon-like peptide-1 and macronutrient composition determines food intake in rats. J Nutr 2001;131:1819–1825.
- Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, et al: Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2004;17:336–342.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.